All posts by: Michael Zand

About Michael Zand

Ferring Makes Foray Into Gene Therapy With FKD Pact – Scrip

Continue reading

2018-05-03 NEWS

Scrip

Ferring Makes Foray Into Gene Therapy With FKD Pact
Scrip
Executive Summary. The Swiss company’s CMO Klaus Dugi tells Scrip that getting the rights to a late-stage bladder cancer gene therapy from Finland’s FKD highlights the transformation that Ferring is undergoing. Already Registered? Sign in to continue

Continue reading

2018-05-03 NEWS

Friedreich’s Ataxia News

UK Pilot Study to Evaluate Effects of Stem Cell Therapy in Friedreich’s Ataxia Patients
Friedreich’s Ataxia News
The clinical benefits of stem cell therapy in Friedreich’s ataxia patients will be assessed in a small pilot study at the University of Bristol in the United Kingdom. Friedreich’s ataxia (FA) is a rare neurodegenerative disorder caused by mutations in

Continue reading

2018-05-03 NEWS

MIT News

Fasting boosts stem cells‘ regenerative capacity
MIT News
As people age, their intestinal stem cells begin to lose their ability to regenerate. These stem cells are the source for all new intestinal cells, so this decline can make it more difficult to recover from gastrointestinal infections or other
Adult Stem Cells Get a Boost from FastingGenetic Engineering & Biotechnology News
Fasting improves stem cells‘ regenerative capacity: studyXinhua
Fasting can help stem cells in the intestine to regenerateZME Science

all 2 news articles »

Continue reading

2018-05-03 NEWS

Myasthenia Gravis News

#AAN2018 – Rituxan a Promising First-line Immunotherapy in Late-onset MG, Study Suggests
Myasthenia Gravis News
The researchers analyzed Rituxan’s effectiveness and safety by treating six late-onset MG patients (five women and one man) with the therapy, ultimately evaluating its potential as a first-line immunotherapy. Mean age of myasthenia gravis onset was 66